Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache
This study is ongoing, but not recruiting participants.
Sponsor:
Autonomic Technologies, Inc.
Information provided by (Responsible Party):
Autonomic Technologies, Inc.
ClinicalTrials.gov Identifier:
NCT01255813
First received: December 3, 2010
Last updated: February 24, 2012
Last verified: February 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the proposed clinical study is to evaluate the use of an implanted Neurostimulator to provide Sphenopalatine Ganglion (SPG) stimulation for the management of the pain associated with cluster headaches.
| Condition | Intervention |
|---|---|
|
Chronic Cluster Headache |
Device: Stimulation (Sub-perception) Device: Stimulation (Full) Other: Control |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | Sphenopalatine Ganglion Stimulation for the Acute Treatment of Cluster Headache |
Resource links provided by NLM:
Further study details as provided by Autonomic Technologies, Inc.:
Primary Outcome Measures:
- Number of device related Serious Adverse Events (SAEs) [ Time Frame: Implant through the Experimental Period ] [ Designated as safety issue: Yes ]
- Acute Pain Relief response (as defined by patient) [ Time Frame: 15 minutes ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Pain Freedom [ Time Frame: 15 minutes ] [ Designated as safety issue: No ]
- Rescue medication use [ Time Frame: 90 minutes ] [ Designated as safety issue: No ]Use of medications to treat headache pain within 90 minutes after initiating therapy.
- Pain Relief after initiating therapy [ Time Frame: 30 minutes ] [ Designated as safety issue: No ]
- Pain Relief after initiating therapy [ Time Frame: 60 minutes ] [ Designated as safety issue: No ]
- Pain Relief after initiating therapy [ Time Frame: 90 minutes ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 40 |
| Study Start Date: | December 2010 |
| Estimated Study Completion Date: | February 2013 |
| Estimated Primary Completion Date: | June 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Placebo Comparator: Placebo |
Other: Control
No stimulation applied
|
| Experimental: Sub-perception |
Device: Stimulation (Sub-perception)
Stimulation applied below the perception threshold
|
| Experimental: Full Stimulation |
Device: Stimulation (Full)
Stimulation applied above the perception threshold
|
Eligibility| Ages Eligible for Study: | 18 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age from 18 to 65 years old (inclusive).
- Subject has been diagnosed with chronic cluster headache according to the 2004 International Headache Society (IHS) criteria 3.1.2.
- Subject reports a minimum of 4 cluster headaches per week.
- Subject reports dissatisfaction with current cluster headache treatment (Criterion includes both preventive or abortive therapy per the Investigator's standard of care. Reasons for dissatisfaction with existing headache therapies may include failure of therapies, contraindication, side effects of therapies, or patient refusal of available therapies)
- Subject is able to distinguish cluster headaches from other headaches (i.e., tension-type headaches).
- Subject has the ability to read and comprehend, and to reliably record information as required by the Protocol.
- Subject is able to provide written informed consent prior to participation in the study.
Exclusion Criteria:
- Subject has had a change in type or dosage of prophylactic headache medications < one (1) month prior to study enrollment
- Subject has undergone facial surgery in the area of the pterygopalatine fossa or zygomaticomaxillary buttress ipsilateral to the planned implant site within the last four (4) months.
- Subject has active oral or dental abscess.
- Subject has been treated with radiation to the facial region within the last six (6) months.
- Subject has been diagnosed with any major infectious processes such as osteomyelitis, or primary or secondary malignancies involving the face that have been active or required treatment in the past six (6) months.
- Subject has other significant pain problem that might confound the study assessments in the opinion of the Investigator.
- Subject is a woman of childbearing age who is pregnant, nursing, or not using contraception.
- Subject is currently participating or has participated in the last month in another clinical study in which the subject has, is, or will be exposed to an investigational or non-investigational drug or device.
- Subject is felt to be at risk of non-compliance (e.g., for completing the diary or maintaining a stable headache medicine regimen) in the Investigator's opinion.
- Subject has had previous lesional radio-frequency ablation of the ipsilateral sphenopalatine ganglion (SPG).
- Subject has had blocks of the ipsilateral SPG in the last three (3) months.
- Subject has undergone botulinum toxin injections of the head and/or neck in the last three (3) months.
- Subject has or requires a pacemaker/defibrillator or other implantable device having a sense amplifier.
- Subject has a history of bleeding disorders or coagulopathy or is unable to discontinue anticoagulation, antiplatelet, or GP IIb IIIa inhibitor medication in preparation for the implantation procedure.
- Subject is not suitable for the study for any reason in the judgment of the Investigator.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01255813
Locations
| Belgium | |
| Citadelle Hospital | |
| Liege, Belgium | |
| Denmark | |
| Danish Headache Center, Dept. of Neurology, Glostrup Hospital | |
| Glostrup, Denmark, 2600 | |
| France | |
| CHU de Nice - Hopital Pasteur, Dept. d'Evaluation et Traitement de la Douleur Medecine Palliative | |
| Nice, France, 06002 Nice cedex 1 | |
| Germany | |
| Headache Center, Dept. of Neurology, University Duisburg-Essen | |
| Essen, Germany, 45147 | |
| Institut fur systemische Neurowissenschaften, Universitastsklinikum Hamburg-Eppendorf (UKE) | |
| Hamburg, Germany, 20246 | |
| Spain | |
| Department of Neurology, University Clinic Hospital, University of Valencia | |
| Valencia, Spain, 46010 | |
Sponsors and Collaborators
Autonomic Technologies, Inc.
Investigators
| Principal Investigator: | Jean Schoenen, M.D. | Professor of Functional Neuroanatomy, Leige University |
More Information
No publications provided
| Responsible Party: | Autonomic Technologies, Inc. |
| ClinicalTrials.gov Identifier: | NCT01255813 History of Changes |
| Other Study ID Numbers: | Pathway CH-1 (CIP-001) |
| Study First Received: | December 3, 2010 |
| Last Updated: | February 24, 2012 |
| Health Authority: | Belgium: Federal Agency for Medicinal Products and Health Products Denmark: Danish Medicines Agency France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) Germany: Federal Institute for Drugs and Medical Devices Spain: Agencia Española de Medicamentos y Productos Sanitarios |
Keywords provided by Autonomic Technologies, Inc.:
|
Chronic Cluster Headache |
Additional relevant MeSH terms:
|
Cluster Headache Ganglion Cysts Headache Trigeminal Autonomic Cephalalgias Headache Disorders, Primary Headache Disorders Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Cysts Neoplasms Mucinoses Connective Tissue Diseases Pain Neurologic Manifestations Signs and Symptoms |
ClinicalTrials.gov processed this record on May 19, 2013